Discover
ALMS
Alumis Inc.
26.64
2 x 20.01
2 x 33.76
bid
ask
-
1.50
5.33%
2 @ 04:28 AM
26.47 -0.17 (0.64%)
| Ytd | 172.95% | |
| 1y | 782.12% |
26.17
day range
28.15
3.00
52 week range
30.60
| Open | 27.60 | Prev Close | 28.14 | Low | 26.17 | High | 28.15 | Mkt Cap | 3.40B |
| Vol | 1.21M | Avg Vol | 1.26M | EPS | -1.78 | P/E | N/A | Forward P/E | -9.02 |
| Beta | -0.54 | Short Ratio | 10.63 | Inst. Own | 99.76% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 23.32 | 200-d Avg | 17.45 | 1yr Est | 40.10 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-05-13 | 2026-03 | 0 | N/A | N/A | N/A |
| 2026-03-19 | 2025-12 | 0 | N/A | N/A | N/A |
| 2025-11-13 | 2025-09 | 0 | N/A | -0.14 | -15.22% |
| 2025-11-13 | 2025-09 | 0 | N/A | N/A | N/A |
| 2025-08-13 | 2025-06 | 0 | N/A | N/A | N/A |
| 2025-08-13 | 2025-06 | 0 | N/A | -0.06 | -5.41% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-05-19 | Chardan Capital | Upgrade | Buy | Buy |
| 2026-05-15 | Wells Fargo | Upgrade | Overweight | Overweight |
| 2026-05-15 | Guggenheim | Upgrade | Buy | Buy |
| 2026-05-15 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| 2026-03-30 | Oppenheimer | Upgrade | Outperform | Outperform |
| 2026-03-30 | Chardan Capital | Upgrade | Buy | Buy |
Profile
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-01-08 | AKKARAJU SRINIVAS | Director | 0.00 | Purchase |
| 2025-05-20 | AYURMAYA CAPITAL MANAGEMENT COMPANY, LP | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Stock Award(Grant) |
| 2025-03-31 | BABLER MARTIN | Chief Executive Officer | 0.00 | Purchase |
| 2025-07-28 | BRADLEY MARK CHRISTOPHER | Officer | 88.78K | Stock Award(Grant) |
| 2026-05-21 | DRAPPA JORN | Officer | 59.34K | Conversion of Exercise of derivative security |
| 2026-01-07 | FORESITE CAPITAL MANAGEMENT VI, LLC. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | Blackrock Inc. | 7.17M | 191.03M | 5.81% |
| 2026-03-30 | Deep Track Capital, Lp | 6.77M | 180.42M | 5.49% |
| 2026-03-30 | Samsara BioCapital, LLC | 6.35M | 169.04M | 5.14% |
| 2026-03-30 | Foresite Capital Management V, LLC | 5.90M | 157.10M | 4.78% |
| 2026-03-30 | venBio Partners LLC | 4.53M | 120.64M | 3.67% |
| 2026-03-30 | Foresite Capital Management VI LLC | 4.25M | 113.16M | 3.44% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.03M | 80.67M | 2.45% |
| 2026-04-29 | iShares Trust-iShares Russell 2000 ETF | 1.61M | 42.78M | 1.30% |
| 2026-03-30 | T. Rowe Price Health Sciences Fund, Inc. | 1.19M | 31.66M | 0.96% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 906.13K | 24.14M | 0.73% |
| 2026-04-29 | Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 678.06K | 18.06M | 0.55% |
| 2026-03-30 | T. Rowe Price New Horizons Fund, Inc. | 667.22K | 17.77M | 0.54% |